Scientific exchange · Dr. Andrea Weber

18 Apr 2026 · Phone · Dr. Andrea Weber, McGill University Health Centre · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0194Safety

Safety flag

This record contains a potential adverse-event observation. It has been routed to Pharmacovigilance per SOP-PV-014 and is excluded from AI processing.

Location: McGill University Health Centre
Therapeutic area: Neurology
Country: Canada
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Real-world persistence
Drug interactions

Scientific content used

LMV persistence data summary

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with general neurologist at McGill University Health Centre. Discussed real-world persistence, drug interactions.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0194

Audit history (0)

All create, update and approval events for this record

No audit events in sample data